Impact of glibenclamide pretreatment on outcomes in acute ischemic stroke patients with type 2 diabetes: a retrospective case-control study
Open Access
- 20 August 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
Abstract
Ischemic stroke is a major health concern, particularly in patients with type 2 diabetes mellitus (T2DM), who are at elevated risk. This study aimed to evaluate the prognostic impact of glibenclamide pretreatment on patients with acute ischemic stroke and T2DM. A total of 122 patients with acute ischemic stroke and T2DM were retrospectively analyzed. Based on medication history, patients were categorized into the glibenclamide group (group 1, n = 54) and the control group (group 2, n = 68). Stroke severity at admission was assessed using the National Institutes of Health Stroke Scale (NIHSS), and functional status was evaluated with the Barthel Index (BI) and modified Rankin Scale (mRS). Patients were followed for 3 months. At admission, group 1 demonstrated significantly better neurological function (lower NIHSS) and higher BI scores compared to group 2 (P < 0.05). At 3 months, mortality was 1.9% in group 1 and 5.9% in group 2, though this difference was not statistically significant (χ2 = 0.430, P = 0.512). Adverse events occurred in 7.4% and 10.3% of patients in groups 1 and 2, respectively (P > 0.05), with no drug-related deaths or serious safety concerns. The incidence of hemorrhagic transformation also showed no significant difference (P > 0.05). However, group 1 showed significantly better functional outcomes at 3 months, with higher BI scores and lower mRS scores (P < 0.05), suggesting improved independence and neurological recovery. Glibenclamide pretreatment in patients with acute ischemic stroke and T2DM may confer clinical benefits by reducing stroke severity and enhancing post-stroke functional outcomes, without increasing adverse events.Keywords
Funding Information
- the project from Science and Technology of Ganzhou (2023DXNS4747)
- the project from Science and Technology Department of Sichuan Province (2022YFS0613)
- the Sichuan Provincial Natural Science Foundation (2024NSFSC1823)
This publication has 32 references indexed in Scilit:
- Continuous Glibenclamide Prevents Hemorrhagic Transformation in a Rodent Model of Severe Ischemia-ReperfusionJournal of Stroke and Cerebrovascular Diseases, 2021
- Glimepiride and glibenclamide have comparable efficacy in treating acute ischemic stroke in miceNeuropharmacology, 2020
- Sulfonylurea Receptor 1, Transient Receptor Potential Cation Channel Subfamily M Member 4, and KIR6.2:Role in Hemorrhagic Progression of ContusionJournal of Neurotrauma, 2019
- Patterns of Stroke Between University Hospitals and Nonuniversity Hospitals in Mainland China: Prospective Multicenter Hospital-Based Registry StudyWorld Neurosurgery, 2017
- Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010The Lancet, 2013
- The Sulfonylurea Receptor 1 (Sur1)-Transient Receptor Potential Melastatin 4 (Trpm4) ChannelJournal of Biological Chemistry, 2013
- Glibenclamide Enhances Neurogenesis and Improves Long-Term Functional Recovery after Transient Focal Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 2012
- Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureasAnnals of Neurology, 2012
- Risk of Stroke and Cardiovascular Events After Ischemic Stroke or Transient Ischemic Attack in Patients With Type 2 Diabetes or Metabolic SyndromeArchives of Neurology, 2011
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010